The goal of pharmacotherapy is to reduce morbidity and prevent complications. Although most experience is with standard heparin, low molecular weight heparins may have some role, providing that the patient does not have renal disease. Low molecular weight heparins have not been used clinically. Does not actively lyse but is able to inhibit further thrombogenesis. Prevents reaccumulation of clot after spontaneous fibrinolysis.
Death is the most serious complication.
Organ infarction and limb ischemia may occur. Renal, adrenal, and pulmonary failure followed by multiorgan destruction may occur. If the condition is self-limited, then the patient can recover. Disseminated intravascular coagulation and activated coagulation. Disseminated intravascular coagulation -pathogenesis and management.